Rita S.
- Country
- Portugal
- Department
- Oncology Department
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase 3 Randomized Controlled Trial of Adjuvant mRNA-4157 and Pembrolizumab Versus Placebo and Pembrolizumab in High-Risk Stage II-IV Melanoma
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 110 of 301 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses on advanced therapeutic approaches for triple negative breast cancer (TNBC), particularly in the context of neoadjuvant and adjuvant treatment strategies. Their research encompasses innovative combinations of immunotherapy and chemotherapy for locally advanced breast cancer cases.
- Triple Negative Breast Cancer Management
- Neoadjuvant Therapy Protocols
- Adjuvant Treatment Approaches
The investigator evaluates pathological complete response rates and event-free survival outcomes in breast cancer patients.
Metastatic Breast Cancer
The investigator specializes in treating HER2-positive metastatic breast cancer, with particular attention to cases involving brain metastases. Their work involves evaluating novel targeted therapies, including trastuzumab deruxtecan, for previously treated advanced cases.
- HER2-Positive Breast Cancer Treatment
- Brain Metastasis Management
- Advanced Disease Therapeutics
Their research explores treatment efficacy in patients with varying metastatic presentations.
Therapeutic Innovation
The investigator's work encompasses targeted therapeutic approaches and combination treatment strategies for breast cancer. Their expertise extends to evaluating novel drug combinations and treatment sequences in complex cases.
- Innovative Treatment Protocols
- Clinical Response Assessment
- Treatment Sequence Optimization
The research focuses on developing effective treatment strategies for various breast cancer subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.